`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`APOTEX INC.,
`Petitioners
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2024-00631
`Patent 10,335,462
`______________________
`
`PATENT OWNER’S OPPOSITION TO PETITIONER’S
`MOTION FOR JOINDER
`
`
`
`
`
`
`
`
`PROTECTIVE ORDER INFORMAITON
`
`
`
`
`
`
`
`
`I.
`
`II.
`
`
`
`TABLE OF CONTENTS
`
`Petitioner Does Not Establish Good Cause For Its Untimely Joinder
`Motion ...............................................................................................................................1
`Petitioner’s Request For Consolidation of IPRs On Different Timelines Is
`Nonsensical ......................................................................................................................9
`
`
`
`
`i
`PROTECTIVE ORDER INFORMAITON
`
`
`
`
`
`TABLE OF AUTHORITIES
`
` Page(s)
`
`Cases
`Apple Inc. v. Evolved Wireless, LLC,
`IPR2016-01209, Paps. 7 & 8 (Dec. 21, 2016) .................................................... 10
`Dr. Reddy’s Labs., Inc. v. Novo Nordisk A/S,
`IPR2024-00009, Pap.12 (Nov. 20, 2023) ......................................................... 3, 9
`GlobalFoundries U.S. Inc. v. Godo Kaisha IP Bridge 1,
`IPR2017-00925, Pap.13 (June 9, 2017) ................................................................ 7
`Google Inc. v. Personalweb Techs., LLC,
`IPR2014-00978, Pap.11 (Oct. 30, 2014) .......................................................... 2, 4
`LG Elecs. Inc. v. Jawbone Innovations, LLC,
`IPR2023-01110, Pap.3 (June 23, 2023) .............................................................. 10
`Mylan Pharms. Inc. v. Novo Nordisk A/S,
`IPR2023-00724, Pap.14 (Nov. 9, 2023) ............................................................... 9
`Roche Molecular Systems Inc. v. Illumina, Inc.,
`IPR2015-01091, Pap.18 (Oct. 30, 2015) .............................................................. 6
`Shaw Indus. Grp., Inc. v. Automated Creel Sys., Inc.,
`IPR2013-00584, Pap.20 (Dec. 31, 2013) ...................................................... 2, 4, 5
`Sony Corp. of Am. v. Network-1 Security Sols.,
`IPR2013-00495, Pap.13 (Sept. 16, 2013) ............................................................. 7
`Sony Elecs. Inc. v. Jawbone Innovations, LLC,
`IPR2023-01110, Pap.12 (Feb. 9, 2024) .............................................................. 10
`Sony Elecs. Inc. v. Jawbone Innovations, LLC,
`IPR2023-01119, Pap.14 (Feb. 9, 2024) .............................................................. 10
`Sony Elecs. Inc. v. Jawbone Innovations, LLC,
`IPR2023-01119, Pap.3 (June 23, 2023) .............................................................. 10
`
`ii
`PROTECTIVE ORDER INFORMAITON
`
`
`
`Sun Pharm. Ltd. v. Novo Nordisk A/S,
`IPR2024-00009, Pap.8 (Nov. 28, 2023) ........................................................... 3, 9
`TrickleStar LLC v. Embertec Pty Ltd.,
`IPR2017-00839, Pap.11 (June 10, 2017) .............................................................. 4
`ZTE (USA) Inc. v. Evolved Wireless LLC,
`IPR2016-01277, Pap.8 (Dec. 21, 2016) .............................................................. 10
`Other Authorities
`37 C.F.R. §41.122 ...................................................................................................... 1
`37 C.F.R. §42.5(b) ..................................................................................................... 1
`37 C.F.R. §42.20(c) .................................................................................................... 2
`37 C.F.R. §42.53 ........................................................................................................ 9
`
`
`
`iii
`PROTECTIVE ORDER INFORMAITON
`
`
`
`Patent Owner Novo Nordisk A/S (“PO”) submits this Opposition to
`
`Petitioner’s four-month-late Motion for Joinder (“Motion”/Pap.5) and its
`
`alternative request to “consolidate” its late proceeding with IPR2023-00724 (the
`
`“Mylan IPR”)—an IPR in which a POR has already been filed, and in which a
`
`Reply and Sur-Reply would be filed, and oral argument presented, long before any
`
`institution decision would even be due in this case.
`
`I.
`
`Petitioner Does Not Establish Good Cause For Its Untimely Joinder
`Motion
`No special circumstances exist that would justify waiver of the one-month
`
`time period for requesting joinder. See 37 C.F.R. §42.5(b). Petitioner filed its
`
`copycat petition and motion for joinder on March 1, 2024, almost four months after
`
`the deadline to move to join IPR2023-00724, and about a month and a half after
`
`the Patent Owner Response was filed in IPR2023-00724. 37 C.F.R. §41.122.0F
`
`1
`
`
`
`
`1 Petitioner’s motion for joinder was, itself, also unauthorized as it was not filed
`
`within the Rule 41.122(b) deadline, and Petitioner has not sought (nor shown the
`
`required basis for) permission to file its motion out of time.
`
`1
`PROTECTIVE ORDER INFORMAITON
`
`
`
`As movant, Petitioner has the burden to show entitlement to the requested
`
`relief, and has not shown “special” or “extraordinary circumstance[s]” to justify
`
`waiver of the joinder deadline. Google Inc. v. Personalweb Techs., LLC, IPR2014-
`
`00978, Pap.11, 4-5 (Oct. 30, 2014) (“Simply because the parties in IPR2014-00062
`
`stipulated to new dates for DUE DATES 1 and 2—a common practice in
`
`proceedings before us—does not constitute an extraordinary circumstance that
`
`would persuade us to waive the one-month time limit for Google to file its Motion
`
`for Joinder” even where the request occurred before the POR); Shaw Indus. Grp.,
`
`Inc. v. Automated Creel Sys., Inc., IPR2013-00584, Pap.20, 4-5 (Dec. 31, 2013)
`
`(“We are not persuaded that special circumstances exist that would justify waiver
`
`of the one-month time period for requesting joinder… Petitioner does not contend
`
`that it was unable to file its Petition in the instant proceeding within one month
`
`of July 25, 2013. Rather, it simply preferred to wait and see if the Board granted
`
`its request for rehearing.”)1F
`
`2; 37 C.F.R. §42.20(c) (“The moving party has the
`
`burden of proof to establish that it is entitled to the requested relief”). Here,
`
`Petitioner provides no showing of any “special” or “extraordinary circumstance.”
`
`
`2 Unless stated, all statutory and regulatory citations are to 35 U.S.C. or 37 C.F.R.,
`
`as context indicates, all internal citations omitted, and all emphases/annotations are
`
`added.
`
`2
`PROTECTIVE ORDER INFORMAITON
`
`
`
`Indeed, Petitioner’s brief does not even acknowledge this standard. Petitioner’s
`
`preference to wait to file an IPR, despite knowing of the patent and the IPR it seeks
`
`to join (confirmed in the March 11, 2024 call with the Board), is the opposite of a
`
`3
`special or extraordinary circumstance.2F
`
`Petitioner’s own admissions about the circumstances of its filing shows that
`
`it merely made a business decision to wait to file (waiting for “heightened
`
`
`3 Apotex asserts, without explaining, that the fact that the Board has not issued a
`
`joinder decision in the Dr. Reddy’s Laboratories, Inc. (“DRL”) or Sun
`
`Pharmaceutical Ltd. (“Sun”) IPRs means the joinder deadline here should be
`
`waived. Pap.5, 1-2. But these assertions are irrelevant to whether the untimely
`
`and opposed Apotex joinder motion should be granted, particularly where the
`
`timely DRL and Sun joinder motions were not opposed. Dr. Reddy’s Labs., Inc. v.
`
`Novo Nordisk A/S, IPR2024-00009, Pap.12, 1 (Nov. 20, 2023); Sun Pharm. Ltd. v.
`
`Novo Nordisk A/S, IPR2024-00009, Pap.8, 1 (Nov. 28, 2023). Further, Apotex is
`
`differently situated than DRL and Sun, who have submitted ANDAs and are
`
`parties to parallel litigation, and for whom motivations relating to, e.g., settlement,
`
`may be different. Dr. Reddy’s Labs., Inc. v. Novo Nordisk A/S, IPR2024-00009,
`
`EX2010, 2 (Jan. 26, 2024); Sun Pharm. Ltd. v. Novo Nordisk A/S, IPR2024-00009,
`
`EX2010, 2 (Feb. 29, 2024).
`
`3
`PROTECTIVE ORDER INFORMAITON
`
`
`
`confidence”), which is the opposite of a “special” or “extraordinary circumstance.”
`
`Google, IPR2014-00978, Pap.11, 4-5; Shaw Indus. Grp., IPR2013-00584, Pap.20,
`
`4-5. Here, just as in Shaw, “Petitioner does not contend that it was unable to file
`
`its Petition in the instant proceeding within one month [of institution of the petition
`
`it seeks to join]. Rather, it simply preferred to wait and see if the Board granted its
`
`request for rehearing.” Shaw Indus. Grp., IPR2013-00584, Pap.20, 4-5. Petitioner
`
`has not provided a sufficient excuse for any delay, let alone a four-month one. See
`
`TrickleStar LLC v. Embertec Pty Ltd., IPR2017-00839, Pap.11, 32-33 (June 10,
`
`2017) (denying joinder motion filed five days after deadline).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Petitioner’s own admissions show that it could have timely filed an
`
`IPR with a motion for joinder. Petitioner’s preference to wait to file long after the
`
`4
`PROTECTIVE ORDER INFORMAITON
`
`
`
`deadline does not and cannot constitute special circumstances. Shaw Indus. Grp.,
`
`IPR2013-00584, Pap.20, 4-5.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4 Petitioner provides no documentary evidence supporting the unsubstantiated
`
`assertions of its employee. EX1507.
`
`5
`PROTECTIVE ORDER INFORMAITON
`
`
`
`
`
`
`
`At each step of the way, Petitioner made the business decision not to prepare
`
`the IPR, and to continue to delay filing its Petition. Petitioner’s business decision
`
`is similar to the rejected excuse offered by the petitioner, Roche, in Roche
`
`Molecular Systems Inc. v. Illumina, Inc., IPR2015-01091, Pap.18 (Oct. 30, 2015).
`
`There, Roche waited to file its motion for joinder “nearly four months after trial
`
`was instituted” despite being aware of the proceeding to which it sought joinder,
`
`and despite the acquisition being completed just four days after trial was instituted.
`
`Id. at 9-10. There, like here, “Petitioner has not provided a reason as to why it
`
`waited [months] to file the instant Petition,” let alone “special circumstances that
`
`would justify waiving the one-month time limit for the filing of the Motion for
`
`Joinder.” Id. at 11, 9. The Board in Roche denied joinder noting “Petitioner could
`
`have also filed its own petition at any time, as there is no standing requirement to
`
`file a petition for inter partes review.” Id. at 11. The same is true here.
`
`
`
`
`
`: Petitioner chose to file
`
`past the joinder deadline.
`
`Petitioner cites no case waiving the deadline for joinder under similar
`
`circumstances. Indeed, the only cases Petitioner cites in arguing the Board should
`
`6
`PROTECTIVE ORDER INFORMAITON
`
`
`
`waive the requirements are GlobalFoundries U.S. Inc. v. Godo Kaisha IP Bridge 1,
`
`IPR2017-00925, Pap.13, 8 (June 9, 2017) and Sony Corp. of Am. v. Network-1
`
`Security Sols., IPR2013-00495, Pap.13, 9 (Sept. 16, 2013). Yet those two cases are
`
`easily distinguished. In both of those cases, the copycat petitioner or its parent
`
`attempted to join the original proceeding within the one-month period.
`
`GlobalFoundries, IPR2017-00925, Pap.13, 7-8 (“here Petitioner’s parent company
`
`filed its petitions… within one month of institution in the -1246 Case, then
`
`Petitioner re-filed shortly thereafter to include both entities as real parties-in-
`
`interest.”); Sony Corp., IPR2013-00495, Pap.13, 7-9 (“Petitioners attempted
`
`previously within the one-month time period to be joined”). The later-filed
`
`petitions, for which joinder was ultimately granted, were submitted only because
`
`the timely petitions were denied or to add a real party-in-interest.
`
`GlobalFoundries, IPR2017-00925, Pap.13, 7-8; Sony Corp., IPR2013-00495,
`
`Pap.13, 7-9. Here, Petitioner never attempted to file any IPR or motion for joinder
`
`within a month of institution of the Mylan IPR. Instead, it made the business
`
`5
`decision to wait.4F
`
`
`5 In the event Apotex’s motion for joinder is granted, Apotex consented to the
`
`stipulations agreed to by DRL and Sun so long as the fourth and fifth stipulations
`
`are revised as follows: (1) “In the event Apotex’s Petition is instituted, only
`
`
`
`7
`PROTECTIVE ORDER INFORMAITON
`
`
`
`
`Apotex will be joined to Mylan Pharmaceuticals, Inc. v. Novo Nordisk, A/S,
`
`IPR2023-00724. Apotex’s Petition and related papers will not be joined or added
`
`as part of institution”; (2) “In the event (1) Apotex’s Petition is instituted, (2)
`
`Apotex is joined to the Mylan IPR, and (3) Mylan is terminated before Novo has
`
`had the opportunity to depose an expert for which Mylan filed a corresponding
`
`expert declaration (and within the time period for taking the corresponding
`
`deposition), the parties will meet and confer as to (1) depositions, (2) whether any
`
`substitute expert(s) will be needed and/or deposed on the already-filed expert
`
`declaration(s) or whether the expert declaration(s) themselves will be expunged
`
`and replaced by the declaration(s) filed with one (and only one) of the copycat
`
`petitions, and (3) what sort of adjustment to the schedule, if any, is needed.
`
`Having met and conferred, the parties will then request a call with the Board
`
`regarding these issues”; (3) “Unless Mylan is terminated, Apotex will serve in the
`
`silent understudy role. In the event that either or both (1) Sun’s Petition is
`
`instituted and Sun is joined to the Mylan IPR and (2) DRL is instituted and DRL is
`
`joined to the Mylan IPR, only one of the joined Petitioners should take the lead
`
`role, and the other(s) should assume the understudy role”; (4) “In the event that
`
`Apotex’s Petition is instituted and Apotex is joined to the Mylan IPR, Apotex shall
`
`not be permitted to raise any new grounds not instituted by the Board in the Mylan
`
`
`
`8
`PROTECTIVE ORDER INFORMAITON
`
`
`
`II.
`
`Petitioner’s Request For Consolidation of IPRs On Different Timelines
`Is Nonsensical
`Petitioner, without authorization, used its joinder motion to alternatively
`
`request consolidation of this IPR with the Mylan IPR, asserting it is appropriate for
`
`the same reasons as joinder. Pap.5, 11. First, this is an improper attempt to end-
`
`run the joinder deadline without justification. Second, because of Petitioner’s
`
`extensive delay in filing its IPR, the schedules in this IPR and the Mylan IPR
`
`would be entirely incompatible. Indeed, in the Mylan IPR, the POR was already
`
`filed on January 17, 2024, the Reply is due on May 1, 2024, and the Sur-Reply is
`
`due on June 12, 2024. Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724,
`
`Pap.14, 1 (Nov. 9, 2023). But even the institution decision in this IPR is not due
`
`until September 12, 2024.
`
`
`IPR, or introduce any argument not already introduced by Mylan”; (5) “With
`
`regard to the taking of testimony, in the event that Apotex’s Petition is instituted
`
`and Apotex is joined to the Mylan IPR, Apotex will abide by 37 C.F.R. §42.53 and
`
`any agreement between the Patent Owner and Mylan.” Dr. Reddy’s Labs.,
`
`IPR2024-00009, Pap.12, 1-3; Sun Pharm. Ltd., IPR2024-00009, Pap.8, 1-3.
`
`9
`PROTECTIVE ORDER INFORMAITON
`
`
`
`Petitioner’s citation to Sony Elecs. Inc. v. Jawbone Innovations, LLC,
`
`IPR2023-01110, Pap.12 (Feb. 9, 2024) is also distinguishable.5F
`6 Pap.5, 11. The
`
`joined petitions there were instituted within two days of one another and
`
`consolidated with each other only about a month after institution. Sony Elecs.,
`
`IPR2023-01119, Pap.14, 2. Further, the Petitioners in the two IPRs that were
`
`ultimately consolidated had both filed timely joinder motions to join an earlier IPR,
`
`which was terminated before joinder. LG Elecs. Inc. v. Jawbone Innovations, LLC,
`
`IPR2023-01110, Pap.3, 3 (June 23, 2023) (filed motion for joinder on June 23,
`
`2023 where the proceeding petitioner sought to join was instituted May 24, 2023);
`
`Sony Elecs. Inc. v. Jawbone Innovations, LLC, IPR2023-01119, Pap.3, 3 (June 23,
`
`2023) (same). And in ZTE (USA) Inc. v. Evolved Wireless LLC, IPR2016-01277,
`
`Pap.8 (Dec. 21, 2016), the petitions were instituted on the same day as each other,
`
`and consolidated at the same time. See Apple Inc. v. Evolved Wireless, LLC,
`
`IPR2016-01209, Paps. 7 & 8 (Dec. 21, 2016).
`
`
`6 PO assumes Petitioner intended to cite Sony Elecs. Inc. v. Jawbone Innovations,
`
`LLC, IPR2023-01119, Pap.14 (Feb. 9, 2024) or LG Elecs. Inc. v. Jawbone
`
`Innovations, LLC, IPR2023-01110, Pap.12 (Feb. 9, 2024), which are the same
`
`document.
`
`10
`PROTECTIVE ORDER INFORMAITON
`
`
`
`Petitioner’s request for consolidation should be denied for all the reasons
`
`joinder should be denied, and because consolidation is not appropriate (or feasible)
`
`for two IPRs instituted at such vastly different points in time.
`
`Dated: April 1, 2024
`
`
`
`
`Respectfully submitted,
`
`By: /Megan Raymond/
`J. Steven Baughman (Reg. No. 47,414)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5832
`steve.baughman@groombridgewu.com
`
`Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5878
`megan.raymond@groombridgewu.com
`
`Michael Milea (Reg. No. 71,863)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`565 5th Avenue, Suite 2900
`New York, NY 10017
`P: (332)-269-0029
`Mike.milea@groombridgewu.com
`
`Joshua Reich (Reg. No. 75,338)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`565 5th Avenue, Suite 2900
`New York, NY 10017
`P: (332)-269-0024
`Joshua.reich@groombridgewu.com
`
`Attorneys for Patent Owner Novo Nordisk A/S
`11
`PROTECTIVE ORDER INFORMAITON
`
`
`
`PAGE COUNT CERTIFICATE
`The undersigned certifies that the foregoing PATENT OWNER’S
`
`OPPOSITION TO PETITIONER’S MOTION FOR JOINDER complies with the
`
`15-page limitation in 37 C.F.R. §42.24(a)(1)(v).
`
`Dated: April 1, 2024
`
`
`
`
`
`Respectfully Submitted,
`
`/Megan Raymond/
`By:
`Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN &
`STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5878
`megan.raymond@groombridgewu.com
`
`
`12
`PROTECTIVE ORDER INFORMAITON
`
`
`
`CERTIFICATE OF SERVICE
`
`It is certified that a copy of the following document has been served in its
`
`entirety on the patent owner as provided in 37 CFR §42.205:
`
`The copy has been served on April 1, 2024 by causing the aforementioned
`
`document to be electronically mailed to the following attorneys of record for
`
`Petitioner listed below:
`
`John J. Molenda
`Lawrence Kass
`Kyler Doh
`Michael I. Green
`Semaglutide@Steptoe.com
`
`
`Dated: April 1, 2024
`
`
`
`
`
` Respectfully submitted,
`
`By: /Sayem Osman/
`Sayem Osman
`
`
`
`13
`PROTECTIVE ORDER INFORMAITON
`
`